Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET-UC Phase 2b study of guselkumab + golimumab in ulcerative colitis
jRCT2031220308Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of guselkumab, golimumab and guselkumab + golimumab in autoimmune colitis (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants with clinical remission at Week 48. Started May 2023; status: active, not recruiting.
02
Drugs
guselkumabgolimumabguselkumab + golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031220308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220308.